{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:54:42Z","timestamp":1779339282836,"version":"3.51.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.toxlet.2003.12.070","type":"journal-article","created":{"date-parts":[[2004,3,14]],"date-time":"2004-03-14T10:07:16Z","timestamp":1079258836000},"page":"111-122","source":"Crossref","is-referenced-by-count":74,"title":["Safety of 5-hydroxy-l-tryptophan"],"prefix":"10.1016","volume":"150","author":[{"given":"Yesu T.","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manashi","family":"Bagchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasis","family":"Bagchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry G.","family":"Preuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2003.12.070_BIB1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s002040050102","article-title":"Identification of four metabolites of 3-(phenylamino)alanine, a constituent of l-tryptophan products implicated in eosinophilia syndrome in rats","volume":"68","author":"Adachi","year":"1994","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002040050169","article-title":"Accumulation of 3-(phenylamino)alanine, a constituent in l-tryptophan products implicated in eosinophilia\u2013myalgia","volume":"69","author":"Adachi","year":"1995","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0447.1991.tb05574.x","article-title":"Low brain uptake of l-[11C]-5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers","volume":"83","author":"Agren","year":"1991","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00346485","article-title":"The treatment of depression with l-5-tryptophan versus imipramine: results of two open and one double-blind study","volume":"224","author":"Angst","year":"1977","journal-title":"Arch. Psychiatr. Nervenkr."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1126\/science.87.2257.308","article-title":"The preparation of dopa-melanin","volume":"87","author":"Arnow","year":"1938","journal-title":"Science"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(91)90254-Z","article-title":"Excessive dietary tryptophan enhances plasma lipid peroxidation in rats","volume":"88","author":"Aviram","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB7","first-page":"1985","article-title":"Etude clinique du 5-hydroxytryptophan dans les etats depressifs du troisieme age","volume":"50","author":"Barlet","year":"1973","journal-title":"Cah. Med. Lyon"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00313460","article-title":"5-OH-Tryptophan in migraine: clinical and neurophysiological considerations","volume":"225","author":"Boiardi","year":"1981","journal-title":"J. Neurol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB9","first-page":"357","article-title":"Serotonin precursors in migraine prophylaxis","volume":"33","author":"Bono","year":"1982","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-2982.1984.0403159.x","article-title":"l-HTP treatment in primary headaches: an attempt in clinical identification of responsive patients","volume":"4","author":"Bono","year":"1984","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB11","doi-asserted-by":"crossref","unstructured":"Brodie, H.K.H., Sack, R., Siever, L., 1973. Clinical studies of l-5-hydroxytryptophan in depression. In: Barchas, J., Usdin, E. (Eds.), Serotonin and Behavior. Academic Press, New York, pp. 549\u2013559.","DOI":"10.1016\/B978-0-12-078150-8.50071-2"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00004714-198706000-00002","article-title":"5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects","volume":"7","author":"Byerley","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ajcn\/56.5.863","article-title":"Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan","volume":"56","author":"Cangiano","year":"1992","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/030006059001800304","article-title":"Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome","volume":"18","author":"Caruso","year":"1990","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB15","unstructured":"Centers for Disease Control, 1989a. Eosinophilia\u2013myalgia syndrome: New Mexico. Morb. Mortal. Wkly. Rep. 38, 765\u2013767."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB16","unstructured":"Centers for Disease Control, 1989b. Eosinophilia\u2013myalgia syndrome: New Mexico, Minnesota, Oregon and New York. Morb. Mortal. Wkly. Rep. 38, 785\u2013788."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB17","first-page":"1527","article-title":"l-Tryptophan induced eosinophilia\u2013myalgia syndrome","volume":"17","author":"Chartash","year":"1990","journal-title":"J. Rheumatol."},{"issue":"Suppl. 46","key":"10.1016\/j.toxlet.2003.12.070_BIB18","first-page":"93","article-title":"Animal models of the eosinophilia\u2013myalgia syndrome","volume":"23","author":"Clauw","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1192\/S0007125000220655","article-title":"Lithium, imipramine and hydroxytryptophan in resistant depression","volume":"152","author":"Conte","year":"1988","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB20","first-page":"269","article-title":"Tryptophan-induced eosinophilia\u2013myalgia syndrome","volume":"153","author":"Criswell","year":"1990","journal-title":"West. J. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1172\/JCI114902","article-title":"l-Tryptophan implicated in human eosinophilia\u2013myalgia syndrome causes fascitis and perimyositis in the Lewis rat","volume":"86","author":"Crofford","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB22","first-page":"239","article-title":"Serotonin precursors in chronic primary headache. A double-blind cross-over study l-5-hydroxytryptophan versus placebo","volume":"29","author":"De Benedittis","year":"1985","journal-title":"J. Neurosurg. Sci."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB23","first-page":"425","article-title":"Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study\u2014l-5-HTP versus placebo","volume":"13","author":"De Giorgis","year":"1987","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-1781(90)90096-N","article-title":"Behavioral, neuroendocrine and biochemical effects of 5-hydroxytrptophan administration in panic disorder","volume":"31","author":"Den Boer","year":"1990","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB25","first-page":"354","article-title":"Environmental pathology. Mast cell and eosinophil infiltration in intestinal mucosa of Lewis rats treated with l-tryptophan implicated in human eosinophilia\u2013myalgia syndrome","volume":"4","author":"De Schryver-Kecskemeti","year":"1991","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB26","doi-asserted-by":"crossref","unstructured":"Dryhurst, G., 1998. Putative endogenous neurotoxins derived from the biogenic amine neurotransmitters. In: Moser, A. (Ed.), Pharmacology of Endogenous Neurotoxins. Birkh\u00e4user, Basel, pp. 63\u2013128.","DOI":"10.1007\/978-1-4612-2000-8_4"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB27","first-page":"385","article-title":"Constituents of West African medicinal plants. XVI. Griffonin and griffonilide, novel constituents of Griffonia simplicifolia","volume":"39","author":"Dwuma-Badu","year":"1976","journal-title":"Lloydia"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB28","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/WNL.44.12.2390","article-title":"1,1\u2032-Ethylidenebis[tryptophan] includes pathologic alterations in muscle similar to those observed in the eosinophilic\u2013myagia syndrome","volume":"44","author":"Emslie-Smith","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB29","first-page":"381","article-title":"Eosinophilia\u2013myalgia syndrome associated with 5-OH-tryptophan. Description of a case","volume":"82","author":"Farinelli","year":"1991","journal-title":"Recent Prog. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB30","unstructured":"FDA\/CDER, 1998. ANDAs: Impurities in Drug Substances. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, Maryland."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB31","first-page":"93","article-title":"Subtype of affective psychoses classified by response on amine precursors and monoamine metabolism","volume":"2","author":"Fujiwara","year":"1973","journal-title":"J. Oral Pathol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB32","first-page":"1534","article-title":"Eosinophilia\u2013myalgia syndrome associated with tryptophan use","volume":"17","author":"Glickstein","year":"1990","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0013-4694(73)90045-X","article-title":"Effects of 5-hydroxytryptophan on sleep of a patient with brain-stem lesion","volume":"34","author":"Guilleminault","year":"1973","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM199003293221301","article-title":"Association of the eosinophilia\u2013myalgia syndrome with the ingestion of tryptophan","volume":"322","author":"Hertzman","year":"1990","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/jps.2600761019","article-title":"Electrochemical oxidation of 5-hydroxytryptophan in acid solution","volume":"76","author":"Humphries","year":"1987","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB36","first-page":"2714","article-title":"Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-l-tryptophan","volume":"26","author":"Johnson","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0190-9622(08)80475-6","article-title":"Development of pseudobullous morphea and scleroderma-like illness during therapy with l-5-hydroxytryptophan and cardidopa","volume":"25","author":"Joly","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0165-0327(85)90046-1","article-title":"l-5-Hydroxytryptophan in the treatment of anxiety disorders","volume":"8","author":"Kahn","year":"1985","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000117687","article-title":"l-5-HTP treatment and serum 5-HT level after l-5-HTP loading on depressed patients","volume":"5","author":"Kaneko","year":"1979","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00005792-199007000-00001","article-title":"l-Tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis: a clinicopathologic and laboratory study of 25 patients","volume":"69","author":"Kaufman","year":"1990","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/oxfordjournals.epirev.a036085","article-title":"Eosinophilia\u2013myalgia syndrome: coming to grips with a new illness","volume":"14","author":"Kilbourne","year":"1992","journal-title":"Epidemiol. Rev."},{"issue":"Suppl. 46","key":"10.1016\/j.toxlet.2003.12.070_BIB42","first-page":"81","article-title":"Tryptophan produced by Showa Denko and epidemic eosinophilia\u2013myalgia syndrome","volume":"23","author":"Kilbourne","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJM198312083092302","article-title":"Clinical epidemiology of toxic-oil syndrome. Manifestations of a new illness","volume":"309","author":"Kilbourne","year":"1983","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-4615-4709-9_58","article-title":"Eosinophilia\u2013myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan","volume":"467","author":"Klarskov","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB45","first-page":"89","article-title":"Structural characterization of a case-implicated contaminant, \u201cpeak X\u201d, in commercial preparations of 5-hydroxytryptophan","volume":"30","author":"Klarskov","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB46","first-page":"241","article-title":"Treatment of essential headache in developmental age with l-5-HTP (cross over double-blind study versus placebo)","volume":"6","author":"Longo","year":"1984","journal-title":"Pediatr. Med. Chir."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000468207","article-title":"5-Hydroxytryptophan (5-HTP) and an MAOI (nialamide) in the treat of depressions","volume":"11","author":"Lopez-Ibor Alino","year":"1976","journal-title":"Int. Pharmacopsychiatry"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB48","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1172\/JCI116300","article-title":"Pathological and immunological effects of ingesting l-tryptophan and 1,1\u2032-ethylidenebis(l-tryptophan) in Lewis rats","volume":"91","author":"Love","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0773.1980.tb02451.x","article-title":"Bioavailability and related pharmacokinetics in man of orally administered l-5-hydroxytryptophan in a steady state","volume":"46","author":"Magnussen","year":"1980","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB50","first-page":"1585","article-title":"Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine","volume":"121","author":"Maissen","year":"1991","journal-title":"Schweiz. Med. Wochenschr."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-113-2-124","article-title":"The clinical spectrum of the eosinophilia\u2013myalgia syndrome associated with l-tryptophan ingestion: clinical features in 20 patients and aspects of pathophysiology","volume":"113","author":"Martin","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9258(18)35614-X","article-title":"The chemistry of melanin. III. Mechanism of the oxidation of dihydroxyphenylalnine by tyrosinase","volume":"172","author":"Mason","year":"1948","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB53","first-page":"399","article-title":"The effect of l-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients","volume":"11","author":"Matussek","year":"1974","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0167-7799(94)90035-3","article-title":"Eosinophilia\u2013myalgia syndrome and tryptophan production: a cautionary tale","volume":"12","author":"Mayeno","year":"1994","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0165-0327(80)90013-0","article-title":"Antidepressant potentiation of 5-hydroxytryptophan by l-deprenil in affective illness","volume":"2","author":"Mendlewicz","year":"1980","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB56","first-page":"1261","article-title":"An eosinophilia\u2013myaligia syndrome related disorder associated with exposure to l-5-hydroxytryptophan","volume":"21","author":"Michelson","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/106002809102501116","article-title":"Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia\u2013myalgia syndrome","volume":"25","author":"Milburn","year":"1991","journal-title":"DICP"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB58","first-page":"223","article-title":"Clinical evaluation of 5-hydroxy-l-tryptophan as an antidepressant drug","volume":"32","author":"Nakajima","year":"1978","journal-title":"Folia Psychiatr. Neurol. Jpn."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB59","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/978-1-4613-0381-7_58","article-title":"Fibromyalgia and migraine, two faces of the same mechanism: serotonin as the common clue for pathogenesis and therapy","volume":"398","author":"Nicolodi","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF01974349","article-title":"Accumulation of 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid in blood and organs of rat. Possible causative substance of eosinophilia\u2013myalgia syndrome associated with ingestion of l-tryptophan","volume":"67","author":"Ogawa","year":"1993","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB61","first-page":"136","article-title":"The biosynthesis of mammalian melanin","volume":"70","author":"Pawalek","year":"1982","journal-title":"Am. Scientist"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB62","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(67)90824-0","article-title":"5-Hydroxytryptophan for depression","volume":"2","author":"Persson","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB63","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archinte.151.3.533","article-title":"Eosinophilia\u2013myalgia syndrome: a clinical case series of 21 patients. New Mexico Eosinophilia\u2013Myalgia Syndrome Study Group","volume":"151","author":"Philen","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/oxfordjournals.aje.a116841","article-title":"Tryptophan contaminants associated with eosinophilia\u2013myalgia syndrome. The eosinophilia\u2013myalgia studies of Oregon, New York and New Mexico","volume":"138","author":"Philen","year":"1993","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB65","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cber.19560890214","article-title":"Die Synthese des [1-Acetylindolyl-(4)]-acetaldehyds, des 4-Cyanmethyl-indols und der Indolyl-(4)-essigs\u00e4ure aus \u03b1-Naphthylamin","volume":"89","author":"Plieninger","year":"1956","journal-title":"Chem. Ber."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000284698","article-title":"A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytrptophan and fluvoxamine","volume":"24","author":"Poldinger","year":"1991","journal-title":"Psychopathology"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/oxfordjournals.epirev.a000804","article-title":"Toxic oil syndrome. The perspective after 20 years","volume":"23","author":"Posada de la Paz","year":"2001","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/030006059202000210","article-title":"Primary fibromyalgia syndrome and 5-hydroxy-l-tryptophan: a 90-day open study","volume":"20","author":"Puttini","year":"1992","journal-title":"J. Intern. Med. Res."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.1928.8.2.245","article-title":"The aerobic oxidases","volume":"8","author":"Raper","year":"1928","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB70","first-page":"809","article-title":"\u201cPrecursor therapy\u201d with active amines. 1. Treatment of depression by l-5-HTP (l-5-hydroxytryptophan)","volume":"73","author":"Sano","year":"1971","journal-title":"Psychiatr. Neurol. Jpn."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB71","first-page":"835","article-title":"\u201cPrecursor therapy\u201d with active amines. 2. Treatment of Parkinson\u2019s disease by l-5-HTP (l-5-hydroxytryptophan)","volume":"73","author":"Sano","year":"1971","journal-title":"Psychiatr. Neurol. Jpn."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB72","first-page":"7","article-title":"l-5-Hydroxytryptophan (l-5-HTP) therapy","volume":"26","author":"Sano","year":"1972","journal-title":"Folia Psychiatr. Neurol. Jpn."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s002040050197","article-title":"Subchronic toxicity of 3-phenylamino alanine, an impurity in l-tryptophan reported to be associated with eosinophilia\u2013myalgia syndrome","volume":"69","author":"Sato","year":"1995","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB74","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199003293221302","article-title":"Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan","volume":"322","author":"Silver","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB75","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1172\/JCI117125","article-title":"A murine model of the eosinophilia\u2013myalgia syndrome induced by 1,1\u2032-ethylidenebis(l-tryptophan)","volume":"93","author":"Silver","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB76","first-page":"288","article-title":"Inhibition of free radical processes by antioxidants\u2014tryptophan and 5-hydroxytryptophan","volume":"43","author":"Simic","year":"1989","journal-title":"Bibl. Nutr. Dieta"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB77","first-page":"792","article-title":"Effect of 5-hydroxytryptophan, a serotonin precursor, on sleep disorders","volume":"1","author":"Soulairac","year":"1977","journal-title":"Ann. Med. Psychol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB78","first-page":"1","article-title":"Three New Mexico women contract unusual medical syndrome","volume":"7","author":"Stieber","year":"1989","journal-title":"Albuquerque J."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0022-3956(75)90025-4","article-title":"Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients","volume":"12","author":"Takahashi","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB80","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cber.19540870909","article-title":"Reaktionen mit Nitrosodisulfonat. VI. Mitteil.: Oxyindole und Indolchinone aus Dihydroindolen","volume":"87","author":"Teuber","year":"1954","journal-title":"Chem. Ber."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB81","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000116030","article-title":"5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial","volume":"25","author":"Titus","year":"1986","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB82","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000117757","article-title":"l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with \u2018therapy-resistant\u2019 depressions","volume":"6","author":"van Hiele","year":"1980","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00422612","article-title":"A pilot study of the predictive value of the probenecid test in the application of 5-Hydroxytryptophan as antidepressant","volume":"25","author":"van Praag","year":"1972","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00421379","article-title":"5-Hydroxytryptophan in combination with clomipramine in \u201ctherapy-resistant\u201d depression","volume":"38","author":"van Praag","year":"1974","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0049-0172(90)90069-R","article-title":"Clinical spectrum of the systemic manifestations of the eosinophilia\u2013myalgia syndrome","volume":"19","author":"Varga","year":"1990","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB86","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00444706","article-title":"Serotonin function in panic disorder: effect of l-5-hydroxytryptophan in patients and controls","volume":"98","author":"Westenberg","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.toxlet.2003.12.070_BIB87","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/1951","article-title":"Problems with over-the-counter 5-hydroxy-l-tryptophan","volume":"4","author":"Williamson","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bioo.1996.0012","article-title":"7-S-Glutathionyl-tryptophan-4,5-dione: formation from 5-hydroxytryptophan and reaction with glutathione","volume":"24","author":"Wu","year":"1996","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0013-4694(71)90147-7","article-title":"Effects of 5-hydroxytryptophan on the sleep of normal human subjects","volume":"30","author":"Wyatt","year":"1971","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB90","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/0006-291X(91)90992-G","article-title":"Effect of synthesized constituents in the l-tryptophan product on the differentiation of eosinophils and the induction of IL-6: a possible cause of eosinophilia\u2013myalgia syndrome","volume":"178","author":"Yamaguchi","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.toxlet.2003.12.070_BIB91","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000118469","article-title":"l-5-Hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression","volume":"20","author":"Zmilacher","year":"1988","journal-title":"Neuropsychobiology"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427404000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427404000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T03:38:11Z","timestamp":1682653091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427404000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0378427404000438"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2003.12.070","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}